Perospirone is a serotonin 5-HT 2A and dopamine D 2 receptor antagonist which originated in Japan. It has been shown that perospirone is metabolized to ID-15036 mainly by CYP3A4 based on an in vitro study. To investigate the metabolism of perospirone in humans, the authors measured the concentration of perospirone and ID-15036 after a single oral dose of perospirone (8 mg) in 10 healthy male subjects, before and during coadministration of carbamazepine, known as a potent inducer of CYP3A4. Before carbamazepine coadministration, the peak plasma concentrations ± SD of perospirone and ID-15036 were 4.0 ± 4.3 and 11.7 ± 7.1 ng/ml, respectively. During carbamazepine coadministration, the concentration of perospirone was decreased below the detection limit, and that of ID-15036 was 6.0 ± 1.7 ng/ml. The concentrations of perospirone and ID-15036 were influenced significantly by the treatment with carbamazepine, and this was probably attributable to the induction of CYP3A4. This study provided an in vivo evidence of involvement of CYP3A4 in the metabolism of perospirone.
Introduction
Perospirone (PER) is a serotonin 5-HT 2A and dopamine D 2 receptor antagonist which originated in Japan. This agent has become widely used because of a better side effect profile than conventional antipsychotics. In the clinical situation, the risk of side effects such as extra-pyramidal symptoms (EPS) induced by PER is likely to increase in proportion to the dose. It is believed that EPS is related to some serotonin/ dopamine interaction (Casey, 1996) . Our previous reports are also supportive to this observation (Takahashi et al., 1998) , in which PER predominantly showed a higher 5-HT 2A /D 2 ratio at lower doses, while the advantage of 5-HT 2A receptor occupancy over D 2 receptor occupancy was lost at higher doses. Such a tendency is very similar to risperidone (Matsubara et al., 1993) , and it has been reported that the incidence of EPS was significantly higher in patients treated with higher doses of risperidone (Marder and Meibach, 1994) . On the other hand, 5-HT 2A receptor occupancy by ID-15036, a major active metabolite of PER, was predominantly observed even at higher doses. This suggests that PER has a biochemical profile similar to that for clozapine and olanzapine (Takahashi et al., 1998) . Consequently, it is assumed that clinical characteristic of ID-15036 is different from that of PER.
In previous case reports, we showed that carbamazepine (CBZ) was effective against perospirone-induced akathisia (Masui et al., 2005) . It has been considered that PER is metabolized to ID-15036 mainly by cytochrome P450 (CYP) 3A4 based on an in vitro study (Mizuno et al., 2003) . Therefore, when PER is administered with CBZ, well known as a potent inducer of CYP3A4 (Wilkinson, 1996) , it is expected that pharmacokinetics of PER can be altered. This pharmacokinetic alteration may be the main mechanism underlying the antiakathisic effect of CBZ.
Here, the authors investigated the pharmacokinetics of PER at single oral dose under concomitant use of CBZ, and 
